Overview
Enodia Therapeutics has raised €20.7 million (approximately $25 million) in seed financing to enhance its discovery platform that utilizes proteomics and machine learning for developing small molecules that degrade disease-driving proteins. The funding round was co-led by Elaia, Pfizer Ventures, and Bpifrance, with additional participation from various investors including Wallonie Entreprendre and the Institut Pasteur.
Products
Loading...
Recent Deals
Investors: Elaia, Pfizer Ventures, Bpifrance, Wallonie Entreprendre, Institut Pasteur
Enodia Therapeutics has raised €20.7 million (approximately $25 million) in seed financing to enhance its discovery platform that utilizes proteomics and machine learning for developing small molecules that degrade disease-driving proteins. The funding round was co-led by Elaia, Pfizer Ventures, and Bpifrance, with additional participation from various investors including Wallonie Entreprendre and the Institut Pasteur.